TRIP-Br2 is overexpressed in multiple human solid tumors and associated with poor prognosis in hepatocellular carcinoma (HCC). (A) Multiple human tumor tissue arrays were immunostained with rabbit anti-TRIP-Br2 polyclonal antibodies. 1: Prostate carcinoma; 2: Squamous cell lung carcinoma; 3: Breast carcinoma; 4: Gastrointestinal stromal tumors, GIST; 5: Renal cell carcinoma; 6: Ovarian carcinoma; 7: Colon carcinoma; 8: Basal cell carcinoma; 9: Hepatocellular carcinoma; 10: Osteosarcoma. The small insert represents 400× magnification of the tissue in each window (shown at 100× magnification). A scale is included in the small insert of window #1 (for all 400× magnified tissue specimens). Immunopositive staining for hTRIP-Br2 is represented by the brown color against the hematoxylin (blue) counterstain. Data was obtained from three independent experiments that were performed in triplicates. (B) TRIP-Br2 overexpression is associated with poor survival of HCC patients (n = 12). The mean survival of patients with TRIP-Br2 overexpression (9 months) was significantly lower than that of HCC patients without TRIP-Br2 overexpression (16 months). The p-value of this survival analysis was determined to be 0.0452 using the Kaplan Meier log rank test.